Following a 49% decline over last year, recent gains may please Caribou Biosciences, Inc. (NASDAQ:CRBU) institutional owners

Simply Wall St.10-17

Key Insights Institutions' substantial holdings in Caribou Biosciences implies that they have significant influence over the company's share price 50% of the business is held by the top 16 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476103354?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2024-10-17 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476103354","market":"hk","top_or_hot":-1,"title":"Following a 49% decline over last year, recent gains may please Caribou Biosciences, Inc. (NASDAQ:CRBU) institutional owners","media":"Simply Wall St.","content":"<div>\n<p>Key Insights  Institutions' substantial holdings in Caribou Biosciences implies that they have significant influence over the company's share price   50% of the business is held by the top 16 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crbu/caribou-biosciences/news/following-a-49-decline-over-last-year-recent-gains-may-pleas-9\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Following a 49% decline over last year, recent gains may please Caribou Biosciences, Inc. (NASDAQ:CRBU) institutional owners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFollowing a 49% decline over last year, recent gains may please Caribou Biosciences, Inc. (NASDAQ:CRBU) institutional owners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crbu/caribou-biosciences/news/following-a-49-decline-over-last-year-recent-gains-may-pleas-9><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Insights  Institutions' substantial holdings in Caribou Biosciences implies that they have significant influence over the company's share price   50% of the business is held by the top 16 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crbu/caribou-biosciences/news/following-a-49-decline-over-last-year-recent-gains-may-pleas-9\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crbu/caribou-biosciences/news/following-a-49-decline-over-last-year-recent-gains-may-pleas-9","article_id":"2476103354","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476103354","pubTimestamp":1729175415,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Key Insights Institutions' substantial holdings in Caribou Biosciences implies that they have significant influence...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","QLD":"纳指两倍做多ETF","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","PSQ":"纳指反向ETF","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","CRBU":"Caribou Biosciences","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SQQQ":"纳指三倍做空ETF",".IXIC":"NASDAQ Composite","QID":"纳指两倍做空ETF","BK4112":"金融交易所和数据","TQQQ":"纳指三倍做多ETF","BK4539":"次新股"},"translate_title":"继去年下跌49%之后，最近的上涨可能会让Caribou Biosciences，Inc.（纳斯达克股票代码：CRBU）的机构所有者感到高兴","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRBU":1,"NDAQ":1,".IXIC":1,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Key Insights  Institutions' substantial holdings in Caribou Biosciences implies that they have significant influence over the company's share price   50% of the business is held by the top 16 shareholders   Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company   Every investor in Caribou Biosciences, Inc. (NASDAQ:CRBU) should be aware of the most powerful shareholder groups.  With 60% stake, institutions possess the maximum shares in the company.   In other words, the group stands to gain the most (or lose the most) from their investment into the company.  After a year of 49% losses, last week’s 11% gain would be welcomed by institutional investors as a possible sign that returns might start trending higher.     Let's take a closer look to see what the different types of shareholders can tell us about Caribou Biosciences.  Check out our latest analysis for Caribou Biosciences NasdaqGS:CRBU Ownership Breakdown October 17th 2024 What Does The Institutional Ownership Tell Us About Caribou Biosciences? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.   As you can see, institutional investors have a fair amount of stake in Caribou Biosciences.  This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong.  When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Caribou Biosciences' historic earnings and revenue below, but keep in mind there's always more to the story. NasdaqGS:CRBU Earnings and Revenue Growth October 17th 2024  Investors should note that institutions actually own more than half the company, so they can collectively wield significant power.    Caribou Biosciences is not owned by hedge funds.      Looking at our data, we can see that the largest shareholder is BlackRock, Inc. with 7.7% of shares outstanding.       In comparison, the second and third largest shareholders hold about 5.2% and 5.0% of the stock.     After doing some more digging, we found that the top 16 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company.    While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing.   Quite a few analysts cover the stock, so you could look into forecast growth quite easily.  Insider Ownership Of Caribou Biosciences The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least.  Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.  Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.   We can see that insiders own shares in Caribou Biosciences, Inc..   It has a market capitalization of just US$176m, and insiders have US$1.8m worth of shares, in their own names.   Some would say this shows alignment of interests between shareholders and the board, though we generally prefer to see bigger insider holdings. But it might be worth checking if those insiders have been selling.   General Public Ownership The general public-- including retail investors -- own 30% stake in the company, and hence can't easily be ignored.   While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.   Private Company Ownership Our data indicates that Private Companies hold 3.7%, of the company's shares.   It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.   Public Company Ownership Public companies currently own 5.2% of Caribou Biosciences stock.   This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.   Next Steps: I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.    Case in point: We've spotted   4 warning signs for Caribou Biosciences  you should be aware of, and 1 of them is potentially serious.      Ultimately the future is most important. You can access this free report on analyst forecasts for the company.  NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476103354"}